SCHEMBL1300775

SCHEMBL1300775

O=C1CCC(=O)[N]1.O=C1CCC(=O)[N]1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.31
TRIM33 Q9UPN9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18634 1.00
SCHEMBL184263 0.84
SCHEMBL9020773 0.84
SCHEMBL1191601 0.82
SCHEMBL5159668 0.81 TRIM24 (0.47) TRIM24TRIM33
SCHEMBL2784295 0.75
SCHEMBL2916501 0.69
SCHEMBL5700097 0.67
SCHEMBL10952924 0.67
SCHEMBL2219404 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669285-B2 Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-06-02 US disclosed
EP-3274471-B1 POLYMER TAGGED NUCLEOTIDES FOR SINGLE MOLECULE ELECTRONIC SNP ASSAY UNIV COLUMBIA (US) 2020-05-06 EP disclosed
US-9658234-B2 Method for analysis of compounds with amino group and analytical reagent therefor AJINOMOTO CO., INC. (JP) 2017-05-23 US disclosed
EP-3122751-A1 CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS F. Hoffmann-La Roche AG (CH) 2017-02-01 EP disclosed
US-20170008913-A1 CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2017-01-12 US disclosed
US-20160139134-A1 METHOD FOR ANALYSIS OF COMPOUNDS WITH AMINO GROUP AND ANALYTICAL REAGENT THEREFOR AJINOMOTO CO., INC. (JP) 2016-05-19 US disclosed
US-9274123-B2 Method for analysis of compounds with amino group and analytical reagent therefor AJINOMOTO CO., INC. (JP) 2016-03-01 US disclosed
EP-2522367-B1 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2016-01-20 EP disclosed
WO-2015144609-A1 CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-10-01 WO disclosed
US-9107956-B2 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2015-08-18 US disclosed
EP-2125027-A2 DE NOVO SYNTHESIS OF CONJUGATES Nektar Therapeutics (US) 2009-12-02 EP disclosed
WO-2008112286-A9 DE NOVO SYNTHESIS OF CONJUGATES NEKTAR THERAPEUTICS AL CORP (US) 2008-12-18 WO disclosed
WO-2008112286-A2 DE NOVO SYNTHESIS OF CONJUGATES NEKTAR THERAPEUTICS (US) 2008-09-18 WO disclosed
WO-2008112289-A2 OLIGOMER-PROTEASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2008-09-18 WO disclosed
US-20060286673-A1 Method for analysis of compounds with amino group and analytical reagent therefor AJINOMOTO CO. INC (JP) 2006-12-21 US disclosed
US-7148069-B2 Method for analysis of compounds with amino group and analytical reagent therefor AJINOMOTO CO., INC. (JP) 2006-12-12 US disclosed
US-20050079624-A1 Method for analysis of compounds with amino group and analytical reagent therefor AJINOMOTO CO., INC (JP) 2005-04-14 US disclosed
EP-1481000-A2 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2004-12-01 EP disclosed
EP-1475632-A1 METHOD OF ANALYZING AMINOFUNCTIONAL COMPOUND AND ANALYTICAL REAGENT Ajinomoto Co., Inc. (JP) 2004-11-10 EP disclosed
WO-2003062265-A2 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669285-B2 Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors LPAR1, ENPP2, LPCAT1 TRIM24 3785/4885TRIM33 4880/4885
US-20170008913-A1 CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS LPAR1, ENPP2, LPCAT1 TRIM24 3785/4885TRIM33 4880/4885
US-20160139134-A1 METHOD FOR ANALYSIS OF COMPOUNDS WITH AMINO GROUP AND ANALYTICAL REAGENT THEREFOR CTH, VIP, SLC7A11 TRIM24 2037/4885TRIM33 1789/4885
US-20050079624-A1 Method for analysis of compounds with amino group and analytical reagent therefor CTH, VIP, SLC7A11 TRIM24 2037/4885TRIM33 1789/4885
US-20060286673-A1 Method for analysis of compounds with amino group and analytical reagent therefor CTH, VIP, SLC7A11 TRIM24 2037/4885TRIM33 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.